Paiji Medical-B rose over 10%, with H1 revenue up 17.4% to 23.1% YoY, and TAVR implant volume increasing by approximately 36.5%

Paiji Medical-B rose over 10%, reaching 4.69 HKD with a 9.07% gain as of press time, and a turnover of 4.3929 million HKD.

In terms of news, Paiji Medical announced that the group's revenue for the first half of 2026 is expected to be approximately RMB 415 million to 435 million, representing a year-on-year growth of about 17.4% to 23.1%. The revenue growth is mainly attributed to the continuous expansion of transcatheter valve therapy business, driven by the successful commercialization of new indication products; the neurointervention business continues to grow under the promotion of self-developed product penetration and strategic cooperation.

The total number of TAVR implants during the period was approximately 2,830 units, a significant increase of about 36.5% compared to the same period last year based on implant volume. Hospital coverage has expanded to over 850 in the Greater China region. TaurusTrio, designed specifically for aortic regurgitation (AR), has completed commercialization, with over 660 cases implanted in mainland China, showing good market acceptance.

Source: Zhitong Finance

$PEIJIA-B(09996.HK)